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Abstract
Purpose Early recognition improves the prognosis of
isocyanate asthma. A major unanswered question is whe-
ther IgE-dependent mechanisms are of diagnostic value?
Our objective was to appraise serological methods using
various methylenediphenyl diisocyanate (MDI)-albumin
conjugates and weigh up the data versus the outcome of
standardized comprehensive clinical diagnostics to evalu-
ate the viability of immunological analysis in supportive
MDI-asthma diagnosis (OAI).
Methods Specific IgE (sIgE) and IgG (sIgG) binding
was measured with fluorescence enzyme immunoassay in
43 study subjects (using conjugates prepared in-vapor,
in-solution and commercial preparations). The differential
clinical diagnosis included standardized measurement of
pulmonary function, non-specific bronchial hyper-respon-
siveness, specific MDI-prick test (MDI-SPT) and specific
inhalation challenge (MDI-SIC).
Results Detailed diagnostic scheme allows the differen-
tial OAI and MDI-induced hypersensitivity pneumonitis
(PI). The presumed OAI diagnoses were confirmed in 84 %
(45 % cases having demonstrable sIgE antibodies) with RR
5.7, P [ 0.001, when OAI diagnosis is correlated with
MDI-SIC/MDI-SPT (RR 1.28 for MDI-SIC alone); sIgG
antibodies were clinically relevant for PI and not for the
OA diagnosis. MDI-specific IgE data generated with
commercial ImmunoCAP preparations show high correla-
tion with our in-vapor generated MDI conjugates.
Conclusions Isocyanate-specific IgE antibodies are not
always detectable but their presence is strongly predictive
of OAI and supportive for the diagnosis. MDI-SPT can be a
valuable parameter differentiating OAI and PI. We have
confirmed and extended published data showing that iso-
cyanate-albumin conjugates perform better in specific
antibody assays when prepared with volatile phase for-
mulations and would like to stress additionally the neces-
sity for further refinements and standardization in clinical
diagnostics procedures.
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4,40-diisocyanate)  Specific IgE antibodies 
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Hypersensitivity pneumonitis  Isocyanate alveolitis
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Introduction
Asthma is generally acknowledged as a critical endpoint
after exposure to isocyanates (Malo and Chan-Yeung 2009;
Maestrelli et al. 2009; Mapp et al. 1994), like 4,40-methy-
lenediphenyl diisocyanate (MDI) the most commonly used
isocyanate. Individuals applying adhesives, paints, foams
and other products (in construction, mining, agriculture, the
shoe and automobile industries, or in orthopedic surgery)
may be exposed to various volatile forms of MDI, accounting
for about 60 % of global isocyanate consumption (World-
Health-Organization 2000). The unequivocal diagnosis of
occupational asthma after isocyanate exposure is difficult. A
major unanswered question is whether IgE-dependent
mechanisms are of diagnostic value or else are the available
IgE tests inadequate for the purpose?
Reactive volatile isocyanates can access epithelial and
mucosal compartments during inhalation and produce
complexes with endogenous proteins, promoting their
antigenicity in vivo. To elucidate the specific immune
responses to such small-molecular-weight environmental
chemicals in vitro, their conjugation with a relevant carrier
host protein like albumin is needed. The structure of nat-
urally occurring conjugates might influence their biological
availability, half-life and antibody-binding capacity.
Inflamed airways characteristic of asthma may result from
an allergic reaction to these conjugates, with the generation
of specific IgE antibodies. From the clinical perspective,
isocyanate asthma is expected to be associated with the
production of isocyanate-specific IgE antibodies detectable
in immunological tests. However, the existing immunodi-
agnostic methods detect allergen-specific IgE antibodies
mostly in a minority (20–50 %) of the patients suffering
from isocyanate asthma (Wisnewski and Jones 2010). The
reason is still unclear. Is it possible that isocyanate asthma
has a different etiology from environmental asthma or that
the pathophysiological mechanisms are, at least in part,
IgE-independent? Or simply that the IgE antibodies remain
undetected because the sampling time is too late after
exposure? Or that the available formulations used in the
conventional immunological tests are inappropriate? Fun-
damental to this dilemma is the appropriateness of the
isocyanate-protein conjugates used in any antibody detec-
tion assays and their relevance to the immunogenic hap-
tenic complexes (or newly formed antigenic determinants)
formed during the pathophysiological conditions.
Various serological tests described in the literature use
different isocyanate-albumin conjugates preparations to
detect immunological responses. Published data obtained
using HDI and TDI conjugates generated with their vapor
phase suggest that there may be antigenic differences (in-
vapor phase generated isocyanate-albumin conjugates
versus in-solution phase) related to the biophysics of the
conjugation reaction (Wisnewski et al. 2004; Wisnewski
2007). Furthermore, it was considered that vapor phase
exposure would lead to limited isocyanate conjugation with
albumin, which presumably reflects the pathophysiological
conditions during occupational exposure to isocyanates
(Wisnewski 2007). The importance of these findings
should not be underestimated when combining the sero-
logical test results with well-defined clinical data for future
diagnosis and preventive measures with asthma.
Unfortunately, relatively few publications provide all
necessary individual diagnostic parameters with the rele-
vant immunological data, precluding comparisons with
clinical diagnosis (Wisnewski and Jones 2010). Frequently,
either the data on antibody assays (in-house assay used in
most studies) or the clinical information for the individual
patients is lacking (i.e. only positive SIC is provided as
indicator for isocyanate asthma), or it remains unclear how
the dose response and the detection limits (LODs) were
calculated (and if the available analytical standards were
used), making useful comparisons between the clinical
parameters and the serological data difficult. Since clinical
examinations including lung function tests are often
insufficient for reliable isocyanate asthma diagnosis and
the available immunological tests identify only a propor-
tion of the affected subjects, there is a need for improve-
ment and standardization of existing diagnostic tests.
In an attempt to evaluate how the isocyanate conjugates
influence the diagnostic sensitivity of the specific IgE
immuno-fluorescence assay, we have adopted the existing
methods to prepare MDI-HSA (human serum albumin)
conjugates in-vapor and could observe a significant
increase in the assay sensitivity as compared to the con-
jugates prepared in-solution. We have used this improved
serological method to search for isocyanate-specific
antibodies in serum of patients with well-characterized
MDI-related asthma and control subjects. Standardized,
comprehensive clinical diagnosis was performed. The major
aim of the study was to investigate whether IgE-dependent
mechanisms are of diagnostic value for patients with MDI
asthma, to standardize the available antibody tests for
variations in conjugate preparations (the art of the conju-
gation, the incubation time) and the clinical diagnosis for
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isocyanate asthma (vs. hypersensitivity pneumonitis). Data
were collected and analyzed to determine the influence of the
variations in conjugate preparation (in-solution, in-vapor and
the available commercial preparation) on antibody binding
and the relations with the comprehensive detailed clinical
diagnosis. Detailed diagnostic criteria are provided for both
isocyanate asthma and hypersensitivity pneumonitis).
Methods
Study population
We analyzed 43 persons, which include all patients with
occupational exposure to MDI and presumed isocyanate
asthma who were referred to our outpatient clinic by gen-
eral practitioners in the last 5 years (n = 12). Three addi-
tional control groups were also studied: 6 asymptomatic
industrial workers currently exposed to *5 ppb MDI
investigated in the workplace, 12 patients with occupa-
tional baker’s asthma, not exposed to isocyanates, and 13
unexposed healthy control subjects. The median value for
the demographic, clinical and functional characteristics of
the symptomatic patients and the controls were as follows:
patient age 43 year (27–67), controls 46 year (28–61), in
the patient group 91 % were men and in the control group
61 %; the total IgE values for the patient group were
102 kU/L IgE (2–1669), for the control group 92 kU/L
(7–893); the median FEV1/FVC ratio in the MDI-exposed
patient group was 0.79. Smoking status: 33 % of the
patients were smokers, 8 % non-smokers and 58 % ex-
smokers; in the control group: 11 % were smokers, 64 %
non-smokers and 14 % ex-smokers. The patients and
controls filled in questionnaires regarding their workplaces,
working conditions, exposure, respiratory symptoms and
smoking habits (the smoking status was confirmed with
cotinine measurements); The patients underwent an
extensive asthma examination (see Tables 1, 2; Fig. 1 for
details). None of the isocyanate asthma patients (and
controls) was under medication at the time of the study.
The clinical, demographic and functional characteristics of
the individual subjects are delineated in the results, as
appropriate. The study was approved by the Institutional
Ethics Review Board, (IRB0003648, Hamburg, Germany).
Table 1 Clinical diagnosis of symptomatic patients with MDI exposure history
Clinical diagnosis criteria of patients with presumed asthma and MDI exposure history
Individual diagnosis criteria follow the ERS guidelines (see text for details)
Differential diagnosis and exclusion (COPD, pulmonary embolism, congestive heart failure, pulmonary infiltration with eosinophils, vocal
cord dysfunction, aspiration pneumonia, anti-inflammatory medication, mechanical obstruction, tumor)
Conditions, see isocyanate asthma diagnostic flow chart
Key indicators: obstructive ventilation pattern, recurrent wheeze, difficulty in breathing, chest tightness, poor respiratory effort
Typical exposure-related asthmatic symptoms, asthmatic symptoms occur or worsen at work; occupational MDI-related exposure history,
isocyanate exposure assessment, presence of workplace-related bronchial hyperresponsiveness after exposure to MDI, positive MDI-SIC
result, positive MDI-SPT result
Additional criteria considered were
Lung function: FEV1 below lower limit of normal, presence of non-specific bronchial hyperresponsiveness (NSBHR)
Presence of MDI-specific IgE antibodies
Table 2 Diagnosis of MDI hypersensitivity pneumonitis with evaluation points for isocyanate alveolitis
Routine diagnostic procedure for isocyanate alveolitis (with evaluation points)
Case history: typical exposure-related symptoms, see above (3 points)
Auscultation, crackles on lower lung fields (2 points)
Serological test: IgG antibodies to MDI-HSA conjugates (1 point)
Lung function tests: restrictive ventilation pattern, impaired diffusion capacity (2 points)
Chest X-ray: lung infiltrates ground or glass pattern (2 points)
Facultative diagnostic parameters
BAL: lymphocytosis, CD4/CD8 \ 1 (3 points)
Serial lung functions testing demonstrating work-related FVC decline of at least 20 % points)
Specific inhalative challenge test: systemic inflammatory response plus restrictive ventilation response and/or impairment of diffusion
capacity of at least 15 % (4 points)
Systemic inflammatory response (fever, leukocytosis) (3 points)
Positive diagnosis: when at least 10 points
Int Arch Occup Environ Health (2013) 86:417–430 419
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Pulmonary function test
FVC (forced vital capacity) and FEV1 (forced expiratory
volume in 1 s) were measured according to ERS/ATS
recommendations applying reference values from (Brandli
et al. 1996, 2000).
NSBHR (non-specific bronchial hyper-responsiveness)
The protocol for NSBHR testing has been described else-
where (Baur et al. 1998). Briefly, the inhalation challenge
involved serial measurements of FEV1 with progressively
increasing doses of methacholine (up to 0.4 mg as mea-
sured at the mouthpiece). A 20 % fall of FEV1 elicited by
B0.3 mg of methacholine (PC20 \ 0.35) indicates NSBHR
(Baur et al. 1998; Jayet et al. 2005).
SPT (skin-prick testing)
SPT was performed with 20 common allergens following a
protocol described earlier (Budnik et al. 2011; Baur et al.
1994). For specific MDI-SPT, sterilized, purified HSA-
MDI conjugates were prepared: the 96 % sterile albumin
solution (for human use from CSL Behring, Germany) was
mixed (in solution) with sterile liquid monomeric MDI
(Bayer, Germany) until a final concentration of 1 mg/mL
MDI was achieved.
The allergens were gently pricked onto the skin surface
of the volar side of the forearm. Wheal and flare reactions
were read 20 min later (a test result was regarded as
positive when a wheal of at least 3 mm in diameter
appeared, with a surrounding flare, which was larger than
the solvent, that is, negative control). The solvent alone
(0.9 % sodium chloride) and histamine (0.01 mg/mL) were
tested in parallel as negative and positive controls.
SIC (specific inhalation challenge)
The SIC method performed in exposure chamber
(0.5–5.5 ppb for 120 min) described elsewhere (Baur et al.
1994; Budnik et al. 2011). FEV1 was measured before and
every 10 min for the 1st h, then hourly for 7 h. The SIC
result was considered positive when the fall in FEV1 was at
least 20 %.
Clinical diagnosis of patients with MDI exposure
history
The individual asthma diagnosis for each patient followed
the ERS/ATS guidelines (Anees et al. 2011; Moore et al.
2010; Vandenplas et al. 2011; Tarlo et al. 2008; Baur et al.
1998) as described in detail below. See Table 1, for the
schematic diagnostic criteria and supplementary Fig. 1 for
diagnostic flow chart of the MDI-asthma diagnosis (see
Figure 1 in supplementary material).
Facultative diagnostic testing
In case of uncertainness due to clear-cut work-related
symptoms (e.g. associated with the absence of NSBHR),
Fig. 1 The 4,40-MDI-HSA conjugates. a Protein gel analysis (poly-
acrylamide gel electrophoresis, SDS-PAGE) of the 4,4-MDI-HSA
conjugates: lanes 1 = protein standards (the arrows show the
positions for human albumin), 2 = 4,40-MDI conjugate prepared in-
solution (i.s.), 3 = 4,40-MDI conjugate prepared in-vapor (i.v.),
4 = native HSA (no conjugate). b Mass spectrometry analysis
(MALDI-TOF-MS) of 4,40-MDI-HSA conjugates prepared using in-
solution (i.s.) and in-vapor (i.v.) methods
420 Int Arch Occup Environ Health (2013) 86:417–430
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additional spirometry monitoring and/or additional specific
inhalative challenge tests were performed (supplementary
Fig. 1).
Diagnosis of MDI hypersensitivity pneumonitis (MDI
alveolitis)
Diagnosis of MDI hypersensitivity pneumonitis has been
described in detail elsewhere (Baur et al. 1992, 2001;
Merget et al. 2002). Prerequisites of acute or subacute MDI
hypersensitivity pneumonitis are the following:
• Occupational/environmental history: MDI exposure.
• Respiratory as well as systemic symptoms after a lag
period of 3–12 h: fever, shivering, malaise, cough and
shortness of breath.
Diagnostic scheme in case of presumed MDI hyper-
sensitivity pneumonitis is shown in the Table 2.
Exposure assessment
Exposure assessment was performed using the MDA-SPM
toxic gas monitor (Honeywell Analytics, Glinde, Germany)
and was confirmed by biomonitoring (Budnik et al. 2011).
If workplace measurement was not possible, the assess-
ment of exposure was based on occupational case history,
detailed reconstruction of the working conditions, data
provided by industrial hygienists as well as information
provided by the employees.
Preparation of various MDI-HSA conjugates
and immunological analysis
The preparation of MDI-HSA conjugates in-vapor and in-
solution is a modification of previously published methods
(Wisnewski et al. 2004; Sepai et al. 1995; Kumar et al.
2009; Baur 1983). The in-vapor method is based on a
specially constructed 2 chamber-system used to fumigate
the human albumin (99 % pure, globulin free, Sigma,
Germany) solution with vaporized 4,40 MDI (analytical
standard, Riedel-de-Häen, Sigma, Germany). Individual
conjugates, were coupled with biotin and used for the
fluorescence enzyme immune assay detection method
(semi-automatic ImmunoCAP100, Phadia, Freiburg, Ger-
many). Serum-specific IgE is expressed in kilo unit per liter
(kU/L) correlated with the WHO reference of human serum
IgE (1 kU = 2.4 ng/mL). A seven-point dose–response
calibration was performed for each IgE and IgG measure-
ment. For ImmunoCAP-specific IgE, the limit of detection
(LOD) of 0.02 kU/L for IgE and 0.2 mg/L for IgG and the
limit of calibration of 100 kU/L for Commercial Immu-
noCAP conjugates (K76, Phadia) used in routine clinical
laboratories were applied in parallel with similar analytical
procedures (for the calibration curves and control sera). For
validation of the assays, the following controls were
included: pooled positive and negative patient/control sera,
analytical standards (also used as set points for quality
control), HSA solution and biotin control samples. The
measured day to day precision was\12 % RSD. The assay
validation was performed according to the good laboratory
practice. Separate studies with HSA solution showed that
IgE values above 0.02 kU/L and IgG values above 3 mg/L
can be considered as specific (above means ?2 RSD or
10 % analytical variation). The variability between the in-
vapor method and the commercial assay method was:
0.5–20 % (for lower and upper edge of failure) for the IgE
values. For the IgG data, however, the values collected
with commercial CAPs were continuously 5–35 % higher
in all tested subjects.
Total IgE antibodies were determined using respective
commercial Uni-CAP from Phadia.
Detection of MDI-bound to HSA
The protein concentration of each test conjugate was
determined by the method of Bradford (BioRad, Germany).
The concentrations were adjusted by dilution or limited
evaporation on a speed-vac system. The conjugates were
subjected to SDS-PAGE using a 9 % separation gel. The
amount of MDI-bound to HSA was calculated from the
intact protein shift using MALDI-TOF-MS (using CHCA-
matrix) and compared with non-conjugated HSA.
LC-MS/MS measurements
Purified HSA was incubated with MDI and analyzed by
MALDI-TOF mass spectrometry (Applied Biosystems, the
Netherlands) to determine the mass shift of the intact
protein. Additionally, the reacted HSA was digested with
trypsin (without any further treatments, such as disulfide
bond reduction). The digested mixtures were analyzed by
liquid chromatography (LC)-mass spectrometry (MS)
(Applied Biosystems, the Netherlands), and modified
peptides were scanned using neutral loss and precursor ion
scans. Interesting ions were analyzed again with product
ion scans to identify them from their fragmentation spectra
(data not shown).
Data analysis
Immunological data are expressed as mean value. Each
analysis was repeated at least twice with three independent
preparations (except for the assay validation). For corre-
lations between diagnosis probability estimates and the
specific immunoglobulin binding, the relative prevalence
ratios (RR) were calculated from the contingency tables
Int Arch Occup Environ Health (2013) 86:417–430 421
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using a logistic model. Two-sample t tests were applied to
calculate the distribution of the difference. To calculate
correlations, the Person’s correlation test was applied.
When the clinical data were combined in union (i.e.
NSBHR, MDI-SIC, MDI-SPT, sIgE), the results of tests in
combination had to be positive; if any result was negative,
the combination was considered negative. When clinical
lung function parameters were evaluated, the percent of the
predicted lung function values was calculated, applying the
reference values of Brändli et al. (see ‘‘Methods’’). For the
comparison of the binding data between the sera for vari-
ously responding patients, the data for each individual
patient were transformed into a percentage of maximal
binding (i.e. if the maximum binding value was 10 kU/L,
the 10 would be 100 % and other data points were given as
a percentage of this value; if the maximum value was
70 kU/L, then 70 would be 100 %, thus allowing to com-
pare high and low responds within one plot). The patient
sera were measured first individually, and then the samples
were pooled as follows: all IgE-positives (median, 26 kU/
L) gave one pool, all IgG-positives (median, 13 mg/L)
gave another, and two control pools (healthy group and
baker’ asthma patients) were the third and the last group.
When data point for only one conjugate is shown, the
following conditions were chosen: in-vapor conjugates
were used in AmBic buffer, 60 min-incubation (if not
otherwise specified).
To test individual conjugates and to validate the assay, a
pool serum from isocyanate asthmatics was used. All
immunological methods were validated routinely with
control serum samples and additional standard set points
(two analytic standards, one low and one high concentra-
tion were used as set points). Two-sample t tests were
applied to calculate the distribution of the difference. The
data analyses were performed with GraphPAD Prism
Software (GraphPad Software Inc, San Diego, CA).
Results
The antibody binding was higher in MDI-albumin
conjugates prepared with volatile MDI as compared
to the insoluble form, showing concomitant higher rates
of the MDI incorporation on the other hand
We have tested exhaustively isocyanate-albumin conju-
gates with 4,40-diphenylmethane diisocyanates (MDI),
generated in-solution (i.s.) and in-vapor (i.v.) using dif-
ferent buffer systems (i.e. PBS and AmBic buffers) and
incubation times. Compared with unreacted HSA, the
protein gel analysis revealed a distinct molecular weight
shift for the in-vapor prepared MDI conjugates, whereas
the in-solution prepared conjugates produced a broad
smear of additional high-molecular-weight bands (pre-
sumably representing heterogenous protein complexes
cross-linked by di-isocyanates) (Fig. 1a). Figures 1b and 2
depict the comparison between the 4,40-MDI-HSA protein
conjugates in terms of the isocyanate incorporation rate for
protein adducts prepared using formulations with liquid;
i.s. and volatile, i.v. MDI.
When using soluble isocyanate, the MDI incorporation
rates into albumin were higher than with the volatile form
(Fig. 2). Conversely, conjugates prepared using the volatile
MDI form (i.v.) showed much higher specific IgE and IgG
antibody-binding capacities than did the conjugates pre-
pared in the liquid form (i.s.) (Fig. 3a, b). The binding
capacity (specific IgE and IgG binding) of the newly
formed MDI-albumin conjugates was assessed using sera
from patients with MDI-isocyanate asthma and control
subjects (patients with non-isocyanate asthma, no isocya-
nate exposure and healthy control subjects).
In parallel, comprehensive differential clinical diagnosis
schema (including specific inhalation challenges with
MDI) was established (Tables 1, 2; supplementary Fig. 1)
and was applied to the tested subjects. The patient data are
given in the methods section (see also Tables 3, 4). Marked
differences in binding capacities were observed for the
various conjugate preparations, buffers, and incubation
time periods (from 0 to 120 min) for both IgE and IgG
(Fig. 3). The specific IgE binding to MDI-HSA was better
for conjugates prepared in AmBic than in PBS (Fig. 3a, c).
The choice of buffer also had some effect on the amount of
specific IgG binding (see Fig. 3c, d).
There was a linear correlation between both the IgE and
IgG values collected with either our fluorescence immu-
noassay using in-vapor conjugates and the commercially
Fig. 2 The preparation of the MDI-HSA conjugates influences the
4,40-MDI incorporation rates into HSA. The MDI-HSA preparations
in volatile form show lower isocyanate incorporation rates when
compared with conjugates prepared in-solution. MDI incorporation
rate for various 4,40-MDI conjugate prepared in-solution (i.s., filled
square) and in-vapor (i.v., filled circle) was calculated as predicted
number of MDI molecules per HSA molecule
422 Int Arch Occup Environ Health (2013) 86:417–430
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available ImmunoCAPs (Phadia) analysis with r = 1.00
and r = 0.79 (for IgE and IgG, respectively). Because of
this high correlation, one can presume that these com-
mercial conjugates were made in-vapor. All positive and
negative antibody values in reactive and non-reactive
subjects correlated between the two CAP systems within a
permissive assay variability of 0.5–20 % for the absolute
sIgE values. For the IgG data, however, the values col-
lected with commercial CAPs were up to 35 % higher
(resulting in false-positive values in lower range).
Clinical diagnosis and antibody analysis
To address the question on the diagnostic feasibility of
antibody testing for the isocyanate asthma diagnosis, we
have analyzed the data from patients with presumed asthma
diagnosis referred to our polyclinic from general practi-
tioners. In order to evaluate the results of the immuno-
logical tests against the clinical diagnosis, two steps are
needed in each case: a comprehensive diagnostic approach
and validated serological test. Our 12 patients underwent
specific inhalation challenges with MDI (none of the con-
trol subjects did approve for either SIC or MDI-prick tests).
Their atopy status, skin-prick test results, serial lung
function testing, demographic data and clinical diagnosis
are given in Tables 3, 4. Four subjects showed positive
specific IgE reaction (3.3–50.4 kU/L of sMDI-IgE) and 10
had specific IgG antibodies: (3.5–74 mg/L sMDI-IgG); 4
MDI-asthma patients showed low values of sIgG
(3.3–9.6 mg/L sIgG; 0.3–6.6 mg/L higher than the unspe-
cific settled value of 3 mg/L), whereas the 4 hypersensi-
tivity pneumonitis patients had mostly higher sIgG values
(up to 74 mg/L).
Figure 4a shows serum samples for individual patients
with presumed isocyanate asthma (for patient data see
Tables 3, 4). We have observed here that improved IgE
assay (in-vapor vs. in-solution) may enhance the diagnostic
sensitivity for individual patients. Additionally, one patient
(pat#1, Tables 3, 4) was followed over a period of
9.5 years (after first MDI-asthma diagnosis in our outpa-
tient clinic). The patient, man, 27 year old, smoker, with
obstructive ventilation disorder, recurrent wheeze and dif-
ficulty in breathing was working on a machine bending
wood bands (spruce) with heated MDI containing glue for
braces, post and bridges (the later were hand-notched,












































































































Fig. 3 The influence of the MDI-HSA conjugate preparation condi-
tions on antibody-binding capacities in fluorescent enzyme immuno-
assay. Specific IgE(a/c) and IgG(b/d) binding in patients’ sera. a/b
4,40-MDI-HSA conjugates were prepared in-vapor (i.v.) and in-
solution (i.s.) using PBS or AmBic. Specific IgE and IgG binding was
tested using serum from MDI-exposed patients using the validated
ImmunoCAP analysis. Data show different conjugate preparations
(repeated twice, n = 3) tested with pooled patient sera. c/d Sera for
each individual patient were measured and the binding data normal-
ized against maximal binding (to allow comparisons between
individual patients showing different maximal binding rates). Mean
values (with min./max error bars, n = 12) are shown and calculated
for specific IgE and IgG binding. Trend lines were generated using
individual data points for various incubation times and buffers as
indicated. The x-axis shows the incubation time during conjugate
preparation. in-solution, i.s. = squares (filled square, open square) in-
vapor, i.v. = circles (filled circle, open circle); commercial conjugate
preparations = triangles (filled triangle); Phadia, PBS = solid sym-
bols (filled square, filled circle); AmBic = empty symbols (open
square, open circle)
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asthma and suffered dermatitis, showed NSBHR and
positive SIC reactions, was positive to common allergens
in SPT and also showed an immediate-type MDI-SPT
reaction, and his total IgE values was 261 kU/L. Asthma
improved and dermatitis symptoms were not observed after
he changed his job and had no further contact to isocya-
nates in the following check-up periods. The specific IgE
data cover 4 years of MDI exposure and 5.5 years free
from exposure (Fig. 4b). Interestingly, significant levels of
sIgE antibodies persisted in this patient throughout the
4 years subsequent to the MDI exposure. This was a sur-
prising result and contradicts the widely held belief that
sIgE levels decay quickly upon the removal from exposure
to isocyanate. Given the assumed short half-life of IgE (his
specific IgG values were lower than 3 mg/L estimated non-
specific reference values), this might be important for the
diagnosis of patients currently no more exposed to
isocyanates.
Correlation with other diagnostic parameters
and the antibody data
Presumed MDI-asthma cases (group A)
The specific IgE-/IgG-binding data were compared with
other diagnostic parameter (see Tables 1, 2 for diagnostic
parameter and supplementary Fig. 1 for the diagnostic flow
chart). Interestingly, all patients with high specific IgE
binding gave also a positive MDI-skin-prick test result. All
patients in this group also exhibited a positive SIC response
when challenged with MDI. In the patient group without
MDI-sIgE antibodies, all but one had negative MDI-skin-
prick results; NSBHR was both present and absent, the SIC
results were positive and negative, and all had IgG anti-
bodies at low levels. When looking closer at individual
patients, the presumed MDI-asthma diagnosis could be
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Fig. 4 Specific IgE antibody level may persist for several exposure-
free years. a Serum IgE antibody levels for all patients with presumed
MDI-asthma (see Tables 3, 4 for patient details) measured with
fluorescence enzyme immune assay using MDI-HSA conjugates
prepared either, in-solution (i.s., hatched columns), in-vapor (i.v.,
solid white columns), or commercial (Phadia, Pha, black column)
conjugates (see methods in Appendix l for more details). b Serum
sIgE antibody levels for one MDI-asthma patient (pat#1, Tables 3, 4)
in a longitudinal study during MDI exposure and subsequent follow-
up for 4.5 years who developed isocyanate asthma with dermatitis
during the exposure period (sIgE values are shown as solid white
columns). After change in workplace and no exposure to isocyanates
for the last 5 years, his lung function improved but he continued to
exhibit MDI-specific IgE antibodies, but no specific IgG antibodies
(shown as solid gray columns; note that all measured IgG values were
below the reference value \3 mg/L); n.d. = not determined
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course of lung function or SIC in 7 out of 12 patients,
although only 4 patients in this group had specific IgE
antibodies. However, the combination of positive MDI-
SIC, MDI-SPT and specific IgE antibodies correlated with
asthma diagnosis (with RR of 5.7, P \ 0.001, n = 12),
whereas MDI-HSA-specific IgE alone showed RR of 1.28,
P \ 0.50 (when correlated with the clinical OAI diagnosis)
given the limitation of the small patient group. There was
no significant correlation between the presence of IgG
antibodies and asthma diagnosis (RR 0.4, P [ 0.5). Inter-
estingly, patients out of the IgE-negative group were
diagnosed with MDI-induced hypersensitivity pneumoni-
tis, with typical systemic and pulmonary symptoms and
respective MDI-provoked SIC responses. The IgG binding
(in combination with the positive SIC data) could be
positively correlated (RR 1.2, P \ 0.50) with the clinical
diagnosis of PI.
Control groups (B, C, D)
Table 4 also provide data from a field study including a
small group of 6 industrial workers with exposure to MDI
(*5 ppb). The subjects were diagnosed directly in the
workplace (only serum and urine samples were taken to the
laboratory). None of the workers had asthmatic symptoms,
as defined by the questionnaire, and had no evidence of
airway obstruction, with all having FEV1 [ 80 % pre-
dicted and FEV1/FVC higher than predicted-1 SD. How-
ever, 5 had work-related upper respiratory and conjunctival
symptoms diagnosed in the course of examination. None of
these MDI-exposed workers had significant detectable IgE
or IgG antibodies. It has to be noted that both air moni-
toring and the spirometry were performed during the whole
working week.
Table 5 shows control groups: 13 unexposed subjects
and 12 patients with occupational asthma not exposed to
isocyanates (baker’s asthma). None of the unexposed
controls had MDI-specific IgE antibodies, one had sIgG
binding at a low level (3.3 mg/L), and a similar result
showed one control baker’s asthma patient.
Discussion
Are the antibody data valuable for the MDI-asthma
diagnosis?
We could confirm our earlier studies (Baur 1983, 2007),
showing the correlation between specific IgE antibodies
and the diagnosis of isocyanate asthma using validated
fluorescence immunoassay and detailed comprehensive
clinical diagnosis. We did not observe false-positives, and
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sufficient for excluding a diagnosis of isocyanate asthma.
The presence of MDI-HSA-specific IgE antibodies was
associated with immediate MDI-SPT responses and the
clinical diagnosis of isocyanate asthma, although about half
of MDI-asthmatic patients have no detectable specific IgE
antibody. Also, (Tee et al. 1998) came to the conclusion
that IgE is a specific, but insensitive index of occupational
asthma. In a contrary, (Aul et al. 1999) suggested a primary
role for IgG in various subjects with respiratory reactions
to isocyanates. Also, others have documented IgG anti-
bodies in patients with occupational asthma (Hur et al.
2008). Bernstein (Bernstein et al. 1993) recognized 3 MDI-
asthma cases in 243 workers exposed to low MDI levels
and detected both sIgG and sIgE binding to MDI-HSA in 2
out of 3 diagnosed isocyanate asthma cases (unfortunately,
no original antibody levels were provided by the authors).
There is a difference, however, between this study, in
which currently exposed factory workers were screened
and our study aiming to proof the diagnostic values of
antibody testing for patients with already presumed asthma
diagnosis. The most, analyzed collectives differ in the
intensity of the symptoms, and the authors have applied in-
solution conjugates, which appear to be at least 5-times less
sensitive. The same group has analyzed later 9 exposed
workers and 9 non-exposed control subjects and suggested
that IgG might be a primary marker of isocyanate exposure
rather than a diagnostic marker for isocyanate asthma
(Lushniak et al. 1998). In our test group, two patients with
diagnosed clinical asthma had elevated specific IgG anti-
bodies in the absence of a specific IgE signal, one isocy-
anate asthma patient showed neither IgE nor IgG
antibodies specific for MDI-HSA. (Vandenplas et al. 1993)
Table 5 Demographic and clinical and functional characteristics of two control groups: healthy subjects (group c) and asthma patients, not
exposed to isocyanates (group D, patients with baker’s asthma)
Subject Demographic data Immunological status Lung function MDI-specific antibodies Final clinical
diagnosis
















Group C: Unexposed healthy control subjects
19 F 28 No Neg. n.d. n.d. n.d. n.d. \002 \3 H
20 M 28 No Pos. n.d. n.d. n.d. n.d. \0.02 \3 H
21 F 50 No Pos. n.d. n.d. n.d. n.d. \0.02 3.3 H
22 F 54 No Neg. n.d. n.d. n.d. n.d. \0.02 \3 H
23 M 56 No Neg. n.d. n.d. n.d. n.d. \0.02 \3 H
24 M 30 No Pos. 67 n.d. n.d. n.d. \0.02 \3 H
25 F 31 No Neg. 128 n.d. n.d. n.d. \0.02 \3 H
26 M 55 Ex Neg. 27 n.d. n.d. n.d. \0.02 \3 H
27 F 57 No Neg. 272 n.d. n.d. n.d. \0.02 \3 H
28 F 61 No Neg. 7.3 n.d. n.d. n.d. \0.02 \3 H
29 F 47 No Pos. 870 n.d. n.d. n.d. \0.02 \3 H
30 F 43 Yes Neg. 33 n.d. n.d. n.d. \0.02 \3 H
31 M 40 No Pos. 42 n.d. n.d. n.d. \0.02 \3 H
Group D. Asthma patients not exposed to isocyanates
32 M 42 No Pos 83 88 86 neg. \0.02 \3 OAB
33 M 40 No Pos 135 94 92 Pos. \0.02 \3 OAB
34 M 44 No Pos 893 106 90 Pos. \0.02 \3 OAB
35 F 62 Ex Neg 65 115 105 Neg. \0.02 \3 OAB
36 F 41 Yes Pos 197 112 111 Pos. \0.02 \3 OAB
37 M 57 Yes Pos 246 95 80 Pos. \0.02 \3 OAB
38 M 56 Ex Neg 332 85 81 Neg. \0.02 \3 OAB
39 M 50 Ex Pos 33 83 66 Pos. \0.02 \3 OAB
40 M 41 No Pos 22 108 82 Neg. \0.02 \3 OAB
41 M 45 No Pos 101 102 98 Pos. \0.02 \3 OAB
42 M 39 No Pos 323 111 97 Neg. \0.02 \3 OAB
43 M 50 No Neg 153 107 75 Pos. \0.02 4.86 OAB
See Table 1 for details, OAB, occupational baker’s asthma; H, healthy
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described hypersensitivity pneumonitis-like responses in 2
out of 9 wood chip board workers applying MDI. The
authors showed comprehensive diagnosis with detailed
clinical parameter survey; unfortunately, they did not
provide detailed information on the laboratory analysis
precluding any data comparison. (Hur et al. 2008) analyzed
58 car upholstery workers currently exposed to MDI and
reported 5 isocyanate asthma and 2 MDI-induced hyper-
sensitivity pneumonitis cases. The authors measured sIgG
antibodies in 8 and sIgE antibodies in 4 workers and
showed further that the prevalence of specific IgG anti-
bodies to MDI-HSA conjugate was higher (20.7 %) than
for sIgE antibodies (8.6 %). Again, the study was designed
to screen currently exposed subjects in a field study.
We could not confirm that low sIgG levels may provide
a good marker for the MDI exposure, since in our control
group not only 1 out of 6, but also two control subjects
(without isocyanate exposure) showed positive sIgG
results. On the other hand, we cannot rule out that IgG
might be an exposure marker; further studies with both
well-characterized patients and assay methods are needed
to draw firm conclusions.
Immunological analysis
We have observed here that improved IgE assay may
enhance the diagnostic sensitivity for individual patients.
High IgE binding using in-vapor HDI and TDI conjugates
has been shown by others (Wisnewski 2007; Campo et al.
2007) and we have confirmed this for MDI as well, pro-
viding here additional information on commercially
available MDI-CAP method. We could record some false-
positive IgG values in the low range using commercial
Phadia assay. In contrast, high levels of specific IgG anti-
bodies were only associated with hypersensitivity pneu-
monitis (MDI alveolitis) in all assays. Recently, another
group has characterized HSA-MDI conjugates prepared in-
solution with a liquid MDI form and has shown specific
IgG binding for 14 MDI-HSA-reaction sites (Wisnewski
et al. 2010). Since there appears to be no association
between IgG binding and MDI asthma (Lushniak et al.
1998), it would be interesting to test whether the IgG-
specific structures are also related to specific IgE sites.
Data from other groups (Kumar et al. 2009; Wisnewski
2007) indicate significant changes in the shape and charge
of human albumin after exposure to HDI or MDI in
humans or rats. Sabbioni and his group were the first to
characterize the MDI-lysine adducts of albumin formed in
vivo in detail and they found MDI-Lys and AcMD-Lys in
the serum of MDI-exposed workers from construction sites
and factories (Sabbioni et al. 2010). While this is a big step
forward, it is not yet known whether the formation of these
human MDI-albumin-adducts correlates with specific
antibody responses. Further studies using characterized
HSA-isocyanate conjugates in validated immunological
tests and well-defined patient collectives are needed.
In order to better compare between the studies, the
methods for the immunological analysis of the IgE and IgG
antibodies need standardization and validation. Semi-
automatic ImmunoCAP analysis could be the method of
choice, since the RAST methodology (Spiazzi et al. 1991)
is not available any more. It has also to be noted that the
practical clinicians have rarely access to research centers
using their own characterized conjugates for antibody
testing and have to relay rather on the routine laboratories
(using commercially available tests). It is important to test
the validity of such tests and the art of the data interpre-
tation. Only a few studies at all (using either HDI, or TDI
conjugates) have compared different assay methods in-
solution or in-vapor (Wisnewski 2007; Wisnewski et al.
2004); no recent study has made any attempts to compare
the antibody data drawn with the commercial assays, most
of the occupational and environmental practitioners relay
on.
Additionally, we could not find any association with the
amounts of the total IgE or with the atopy status in this
study but it cannot be excluded that the low total IgE status
(as seen in some patients) might reflect a low capability of
producing specific antibodies.
Non-IgE-driven pathomechanisms
It remains also to be clarified how many cases involve non-
IgE pathomechanisms. Analyzing 13 isocyanate asthma
patients (5 with positive and 7 with negative SIC results),
Jones et al. (Jones et al. 2006) proposed a non-IgE-medi-
ated (with Il-5-, CD25- and CD4) mechanism for isocya-
nate asthma, with a reservation that presumably this
assumption might concern the IgE-non-responding group
only. Also, matrix metalloproteinase-9 (MMP-9), ferritin,
and transferrin (Palikhe et al. 2011 and monocyte
chemotractant protein-1 (MCP-1) (Bernstein et al. 2002)
were proposed. Further studies are necessary.
Comprehensive clinical diagnosis is necessary
The diagnosis isocyanate asthma is known to be difficult as
its patterns might be associated with isolated late asthmatic
reaction, a biphasic dual reaction or an atypical reaction
(Tarlo et al. 2008; Curwick et al. 2006; Hendrick 2002).
Diagnosis of isocyanate asthma may be also difficult due to
concurrent inflammatory rhinoconjunctivitis or COPD,
leading to false-positive as well as false-negative diagno-
ses. Careful utilization of several diagnostic parameters is
required for the evaluation of data. (Curwick et al. 2006;
Hendrick 2002). Frequently, analyses of reported clinical
428 Int Arch Occup Environ Health (2013) 86:417–430
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cases relay simply on the opinions of individuals, and
reliance on publications is further compromised by the
frequency of misdiagnosis of occupational asthma. Though
the positive SIC result is considered as a ‘‘gold standard’’
for isocyanate asthma, the comprehensive clinical asthma
diagnosis is far more than SIC only. We found that all SIC-
positive patients with sIgE antibodies and the MDI-asthma
diagnosis have also shown positive MDI-SPT reaction,
whereas SIC-positive hypersensitivity pneumonitis patients
were negative for MDI-SPT response. Since SIC can only
be performed in a few highly specialized centers, this result
might be interesting for those having no access to this
diagnostic test. The attributable proportion of occupational
agents to the total asthma burden is in the range of 5–25 %,
with isocyanates as one of the most important causes
worldwide, reinforcing the acute need for a reliable diag-
nostic tests (Hendrick 2002).
Conclusions
The isocyanate-specific IgE antibodies are not always
detectable but their presence can be predictive of isocya-
nate asthma and supportive for the diagnosis of occupa-
tional asthma. In contrast, the presence of IgG antibody
only appears to be indicative in hypersensitivity pneumo-
nitis and not relevant in cases of isocyanate asthma. The
MDI-specific prick test may provide additional supportive
information, allowing differentiation between isocyanate
asthma and MDI-provoked hypersensitivity pneumonitis.
Thus, a carefully evaluated clinical diagnosis is paramount
in each individual case.
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